关键信息
-
基因名
FCRN-B2M
- 应用
-
别名
FCRN; Neonatal Fc receptor; IgG receptor FcRn large subunit p51
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P55899
-
表达区间
Ala24~Ala365
-
分子量
41kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
FCRN-B2M is a recombinant protein that plays a significant role in the immune system and antigen presentation. The Fc receptor neonatal (FCRN) is crucial for the transport of IgG antibodies and the regulation of their half-life. It binds to the Fc region of IgG and plays a pivotal role in protecting IgG from degradation. Beta-2-microglobulin (B2M), an essential component of major histocompatibility complex (MHC) class I molecules, is pivotal for the stability and expression of these molecules on the cell surface. The investigation of FCRN-B2M fusion protein has gained traction in the context of developing novel therapeutic strategies, particularly in diseases associated with immune dysregulation and cancer. Research suggests that manipulating the interaction between FCRN and IgG may enhance the efficacy and duration of antibody-based therapies. Moreover, understanding the structure and function of FCRN-B2M can provide insights into improving immune response and tailoring treatments for autoimmune diseases and malignancies. Studies are focusing on the challenges associated with protein expression, purification, and optimal use of recombinant technology to maximize therapeutic potential. Overall, FCRN-B2M represents a compelling focus in immunology and biotechnology, combining insights from protein engineering, innate and adaptive immunity, and therapeutic development.
